Mydecine Innovations Group IncCanadian Securities Exchange:MYCOView on OTC Pink - Current Information
- LAST PRICE0.0100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0050/ 3,998
- Ask / Lots0.0100/ 988
- Open / Previous Close0.0100 / 0.0100
- Day Range
- 52 Week Range
- Volume1,287
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MYCO |
|---|---|---|
| 09:32 ET | 1000 | 0.01 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Mydecine Innovations Group Inc | 617.6K | 0.0x | --- |
WPD Pharmaceuticals Inc | 579.9K | -4.0x | --- |
Chitogenx Inc | 415.7K | -0.2x | --- |
Lophos Holdings Inc | 858.6K | -0.7x | --- |
Albert Labs International Corp | 372.1K | -0.1x | --- |
Many Bright Ideas Technologies Inc | 228.9K | -3.3x | --- |
Company Information
Mydecine Innovations Group Inc. is a Canada-based biotechnology company. The Company is engaged in developing medications and therapies to address mental health disorders, such as nicotine addiction and posttraumatic stress disorder (PTSD). The Company conducts research and development on second generation compounds in Canada with a focus on developing and commercializing psychedelic-inspired regulated medicines. The Company has two lead 3,4-Methylenedioxymethamphetamine (MDMA) candidates. The Company is channeling its MYCO-005, MYCO-006, and MYCO-007 families of patent-pending second-generation MDMA and Psilocybin analogs through Applied Pharmaceutical Innovation (API). It utilizes artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them accessible to the general public upon Health Canada and Food and Drug Administration (FDA) approval.
Contact Information
- Headquarters
- 1890-1075 West Georgia StreetVANCOUVER, BC, Canada V6E 3C9
- Phone
- 604-687-2038
- Fax
- 778-372-1790
Executives
- President, Chief Executive Officer, Director
- David Bartch
- Chief Financial Officer
- John Ross
- Chief Operating Officer
- Damon Michaels
- Chief Scientific Officer
- Robert Roscow
- Chief Medical Officer
- Rakesh Jetly
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $617.6K |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.8M |
Mydecine Innovations Group Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.28 |
Book Value | $-0.23 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
